Document is current
Any future updates will be listed below
-
Authors
Cuapio, Angelica
Boulouis, Caroline
Filipovic, Iva
Wullimann, David
Kammann, Tobias
Parrot, Tiphaine
Chen, Puran
Akber, Mira
Gao, Yu
Hammer, Quirin
Strunz, Benedikt
Pérez Potti, André
Rivera Ballesteros, Olga
Lange, Joshua
Muvva, Jagadeeswara Rao
Bergman, Peter
Blennow, Ola
Hansson, Lotta
Mielke, Stephan
Nowak, Piotr
Söderdahl, Gunnar
Österborg, Anders
Smith, C. I. Edvard
Bogdanovic, Gordana
Muschiol, Sandra
Hellgren, Fredrika
Loré, Karin
Sobkowiak, Michal J.
Gabarrini, Giorgio
Healy, Katie
Sällberg Chen, Margaret
Alici, Evren
Björkström, Niklas K.
Buggert, Marcus
Ljungman, Per
Sandberg, Johan K.
Aleman, Soo
Ljunggren, Hans-Gustaf https://orcid.org/0000-0003-0908-7387
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse
Nordstjernan AB
Region Stockholm
Swedish Research Council
Karolinska Institutet
Karolinska Institute
- License Information
-
More Information
Article History
Received: 13 January 2022
Accepted: 21 January 2022
First Online: 8 February 2022
Declarations
:
: The study was approved by the Swedish Medical Product Agency (ID 5.1-2021-5881) and the Swedish Ethical Review Authority (ID 2021-00451). All participants provided written informed consent.
: Not applicable.
: H.G.L. has served on the UK-CIC COVID-19 Oversight Committee, and leads the Karolinska Institutet COVID-19 vaccine group. H.G.L. is the Director of the NextGenNK Competence Center supported by Sweden’s Innovation Agency. Together with E.A., he is the founder and board member of XNK Therapeutics and Vycellix Inc. None of the other authors have declared any conflicts of interest in relation to the present study.
